AP2000001892A0 - Self-replicating vector for DNA immunization against HIV. - Google Patents
Self-replicating vector for DNA immunization against HIV.Info
- Publication number
- AP2000001892A0 AP2000001892A0 APAP/P/2000/001892A AP2000001892A AP2000001892A0 AP 2000001892 A0 AP2000001892 A0 AP 2000001892A0 AP 2000001892 A AP2000001892 A AP 2000001892A AP 2000001892 A0 AP2000001892 A0 AP 2000001892A0
- Authority
- AP
- ARIPO
- Prior art keywords
- vectors
- hiv
- vector
- self
- dna immunization
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 8
- 230000003053 immunization Effects 0.000 title abstract 2
- 238000002649 immunization Methods 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 abstract 1
- 101710150344 Protein Rev Proteins 0.000 abstract 1
- 101710149951 Protein Tat Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108091006104 gene-regulatory proteins Proteins 0.000 abstract 1
- 102000034356 gene-regulatory proteins Human genes 0.000 abstract 1
- 230000028996 humoral immune response Effects 0.000 abstract 1
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000002688 persistence Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI980463A FI105105B (fi) | 1998-02-27 | 1998-02-27 | Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan |
| PCT/FI1999/000152 WO1999043841A1 (fr) | 1998-02-27 | 1999-02-26 | Vecteur autoreproducteur pour l'immunisation par l'adn contre le vih |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2000001892A0 true AP2000001892A0 (en) | 2000-09-30 |
Family
ID=8551073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2000/001892A AP2000001892A0 (en) | 1998-02-27 | 1999-02-26 | Self-replicating vector for DNA immunization against HIV. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1056879A1 (fr) |
| CN (1) | CN1295623A (fr) |
| AP (1) | AP2000001892A0 (fr) |
| AU (1) | AU2626699A (fr) |
| FI (1) | FI105105B (fr) |
| OA (1) | OA11528A (fr) |
| RU (1) | RU2232815C2 (fr) |
| WO (1) | WO1999043841A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI107737B (fi) * | 1999-12-23 | 2001-09-28 | Atso Raasmaja | Plasmidi tyrosiinihydroksylaasigeenin ilmentämiseksi aivoissa |
| FI116851B (fi) | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita |
| EP1279404A1 (fr) * | 2001-07-26 | 2003-01-29 | Istituto Superiore di Sanità | Utilisation de HIV-1 tat fragments ou dérivés pour activer des cellules présentatrices d'antigènes, pour délivrer des molécules cargo pour la vaccination ou pour le traitement d'autres maladies |
| DK1506223T3 (da) | 2002-05-16 | 2006-04-10 | Bavarian Nordic As | Fusionsprotein af regulatoriske/accessoriske HIV-proteiner |
| RU2335540C1 (ru) * | 2006-12-25 | 2008-10-10 | ФГУП Государственный научно-исследовательский институт особо чистых биопрепаратов ФМБА | ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pBMC-nef(A)-hum |
| KR101471043B1 (ko) * | 2009-01-08 | 2014-12-09 | 주식회사 바이오리더스 | 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균 |
| PL3216871T3 (pl) * | 2011-10-17 | 2022-03-21 | Regeneron Pharmaceuticals, Inc. | Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy |
| EP3463290A4 (fr) * | 2016-06-03 | 2019-10-30 | Temple University - Of The Commonwealth System of Higher Education | Régulation à contre-réaction du vih-1 par une stratégie d'édition génique |
| CN110747214B (zh) * | 2019-03-13 | 2021-12-31 | 深圳市臻质医疗科技有限公司 | DNA片段、具有长效表达和细胞特异性结合能力的mRNA-抗体融合分子及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| ES2312170T3 (es) * | 1995-12-29 | 2009-02-16 | Fit Biotech Oyj Plc | Vector episomal y usos del mismo. |
| EP0914444A1 (fr) * | 1996-06-06 | 1999-05-12 | Novartis AG | Vecteurs comprenant des elements sar |
-
1998
- 1998-02-27 FI FI980463A patent/FI105105B/fi not_active IP Right Cessation
-
1999
- 1999-02-26 AU AU26266/99A patent/AU2626699A/en not_active Abandoned
- 1999-02-26 OA OA1200000232A patent/OA11528A/en unknown
- 1999-02-26 EP EP99906279A patent/EP1056879A1/fr not_active Withdrawn
- 1999-02-26 RU RU2000122617/13A patent/RU2232815C2/ru not_active IP Right Cessation
- 1999-02-26 AP APAP/P/2000/001892A patent/AP2000001892A0/en unknown
- 1999-02-26 CN CN99804629A patent/CN1295623A/zh active Pending
- 1999-02-26 WO PCT/FI1999/000152 patent/WO1999043841A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1056879A1 (fr) | 2000-12-06 |
| RU2232815C2 (ru) | 2004-07-20 |
| OA11528A (en) | 2004-05-07 |
| CN1295623A (zh) | 2001-05-16 |
| FI980463A0 (fi) | 1998-02-27 |
| WO1999043841A1 (fr) | 1999-09-02 |
| FI980463L (fi) | 1999-09-27 |
| FI105105B (fi) | 2000-06-15 |
| AU2626699A (en) | 1999-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Berglund et al. | Enhancing immune responses using suicidal DNA vaccines | |
| Donnelly et al. | Antigen presentation and DNA vaccines | |
| CA2509973C (fr) | Particules de replicon d'alphavirus multi-antigenique et procedes | |
| EP1608762B1 (fr) | Replicons d'alphavirus ameliores et produits de recombinaison auxiliaires | |
| EP0879284A4 (fr) | Vecteurs d'expression genique generant une reponse immune specifique d'un antigene et leurs procedes d'utilisation | |
| IL136131A0 (en) | Recombinant vaccines comprising immunogenic attenuated bacteria having rpos positive phenotype | |
| DK0724642T3 (da) | Nukleinsyrevektor, sammensætning indeholdende en sådan vektor og vaccine til immunisering mod hepatitis | |
| FI102382B1 (fi) | Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten | |
| AP2000001892A0 (en) | Self-replicating vector for DNA immunization against HIV. | |
| ZA202309287B (en) | Coronavirus vaccine comprising a mosaic protein | |
| DE69929530D1 (de) | Attenuierte pferdeherpesvirus | |
| Abdelnoor | Plasmid DNA vaccines | |
| DK177298B1 (en) | Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and their Use as Vaccines | |
| CA2538840A1 (fr) | Compositions issues d'un vaccin adn et leurs procedes d'utilisation | |
| Phenix et al. | Cell culture evaluation of the Semliki Forest virus expression system as a novel approach for antigen delivery and expression in fish | |
| IL149415A0 (en) | Adjuvanted genetic vaccines | |
| Monet et al. | The emergence of the next-generation vaccines | |
| ES2367245T8 (es) | Virus recombinante que expresa adn foráneo que codifica cd80 felino, cd28 felino, ctla-4felino o cd86 felino y usos del mismo. | |
| Rawat et al. | An overview of biochemical aspects of DNA Vaccines | |
| Kim et al. | Multiple alternating immunizations with DNA vaccine and replication-incompetent adenovirus expressing gB of pseudorabies virus protect animals against lethal virus challenge | |
| Kasi | Future Vaccines | |
| NIXDORFF | Department of Microbiology and Genetics Darmstadt University of Technology Schnittspahnstr. 10 | |
| Dietzschold et al. | Synthesis of an antigenic determinant of the HSV gD that stimulates the induction of virus-neutralizing antibodies and confers protection against a lethal challenge of HSV. | |
| Rodrı́guez et al. | Enhanced cell-mediated IFN-γ-secreting activity against the HIV-1IIIB V3 peptide of the TAB9 multiepitope after DNA vaccine backbone engineering | |
| Satya et al. | Codon Optimization for DNA Vaccines and Gene Therapy Using Pattern Matching |